The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 12, 2019
Filed:
Aug. 09, 2017
Applicant:
Sova Pharmaceuticals, Inc., La Jolla, CA (US);
Inventors:
Sergio G. Durón, San Diego, CA (US);
Justin Chapman, San Diego, CA (US);
Simon G. Sydserff, San Diego, CA (US);
Srinivas G. Rao, Encinitas, CA (US);
Gregory Stein, San Diego, CA (US);
Assignee:
SOVA PHARMACEUTICALS, INC., La Jolla, CA (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/4245 (2006.01); A61K 31/4196 (2006.01); A61K 31/41 (2006.01); C07D 271/06 (2006.01); C07D 249/08 (2006.01); C07D 257/04 (2006.01); C07D 271/07 (2006.01); C07D 249/10 (2006.01); C07D 249/14 (2006.01); C07D 257/06 (2006.01); C07C 311/51 (2006.01); A61K 45/06 (2006.01); A61K 31/433 (2006.01); A61K 31/445 (2006.01); A61K 31/57 (2006.01); A61K 31/18 (2006.01); A61K 31/192 (2006.01); A61K 31/195 (2006.01);
U.S. Cl.
CPC ...
C07D 271/07 (2013.01); A61K 31/18 (2013.01); A61K 31/192 (2013.01); A61K 31/195 (2013.01); A61K 31/41 (2013.01); A61K 31/4196 (2013.01); A61K 31/4245 (2013.01); A61K 31/433 (2013.01); A61K 31/445 (2013.01); A61K 31/57 (2013.01); A61K 45/06 (2013.01); C07C 311/51 (2013.01); C07D 249/08 (2013.01); C07D 249/10 (2013.01); C07D 249/14 (2013.01); C07D 257/04 (2013.01); C07D 257/06 (2013.01);
Abstract
Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit cystathionine-γ-lyase (CSE). Also described herein are methods for using such CSE inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from CSE inhibition.